Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of composition of demethylated magnesium cantharidate and sorafenib in preparation of anti-hepatoma drugs

A magnesium methyl cantharidinate, anti-liver cancer technology, applied in the field of medicine, to achieve the effect of reducing the amount of use, improving the treatment safety index, and clear curative effect

Active Publication Date: 2021-11-19
ZUNYI MEDICAL UNIVERSITY
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] At present, there are no reports at home and abroad on the research on the combined use of magnesium demethylcantharidinate and sorafenib mentioned in the present invention to inhibit the invasion and metastasis of liver cancer cells by activating FOXO1

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of composition of demethylated magnesium cantharidate and sorafenib in preparation of anti-hepatoma drugs
  • Application of composition of demethylated magnesium cantharidate and sorafenib in preparation of anti-hepatoma drugs
  • Application of composition of demethylated magnesium cantharidate and sorafenib in preparation of anti-hepatoma drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Combination of magnesium demethylcantharidinate and sorafenib inhibits the invasion and metastasis of liver cancer SMMC-7721 cells by activating the expression of transcription factor FOXO1

[0041] This example is divided into 4 groups, control group (no drug added), magnesium demethylcantharidinate group (concentration: 7.5 μM), sorafenib group (concentration: 5 μM), demethylcantharidinic acid Magnesium combined with sorafenib group (concentrations were 7.5 μM, 5 μM).

[0042] Cell invasion assay. After liver cancer SMMC-7721 cells were treated by different groups for 24 h, the cells were collected, resuspended, and inoculated in the upper well of the Transwell chamber with Matrigel at a seeding density of 20,000 cells / well, and 600 μl containing 10% RPMI-1640 medium with fetal bovine serum, 37°C, 5% CO 2 After culturing for 24 h under ambient conditions, the culture medium was discarded, fixed with 4% paraformaldehyde, stained with 1% crystal violet staining soluti...

Embodiment 2

[0047] Combination of magnesium demethylcantharidinate and sorafenib inhibits the invasion and metastasis of liver cancer SK-Hep-1 cells by activating the expression of transcription factor FOXO1

[0048] This example is divided into 4 groups, control group (no drug added), magnesium demethylcantharidinate group (concentration: 10 μM), sorafenib group (concentration: 5 μM), demethylcantharidinic acid Magnesium combined with sorafenib group (concentrations were 10 μM, 5 μM respectively).

[0049] Cell invasion assay. After the liver cancer SK-Hep-1 cells were treated by different groups for 24 h, the cells were collected, resuspended, and inoculated in the upper well of the Transwell chamber with Matrigel at a seeding density of 20,000 cells / well, and 600 μl containing RPMI-1640 medium with 10% fetal bovine serum, 37°C, 5% CO 2 After culturing for 24 h under ambient conditions, the culture medium was discarded, fixed with 4% paraformaldehyde, stained with 1% crystal violet st...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of a composition of demethylated magnesium cantharidate and sorafenib in preparation of anti-hepatoma drugs, the combined composition can effectively treat hepatoma, and the effect is obviously better than that of single drugs of demethylated magnesium cantharidate and sorafenib. The combination of the demethylated magnesium cantharidate and the sorafenib can significantly activate a transcription factor FOXO1 to inhibit invasion and metastasis of liver cancer cells, which indicates that the two have a synergistic effect, and the combined pharmaceutical composition provides a new therapeutic drug for clinical treatment of liver cancer, and has a good clinical application prospect.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a combination composition of magnesium demethylcantharidinate and sorafenib to prepare an anti-liver cancer drug and its application. Background technique [0002] Hepatocellular carcinoma is the third leading cause of cancer-related death worldwide and is characterized by high rates of metastasis and recurrence. More than 80% of HCC patients are diagnosed at an advanced stage, making treatment very limited and prognosis poor. Due to tumor recurrence and metastasis, the 5-year survival rate of liver cancer patients is still less than 20%. Despite the emergence of various strategies for the treatment of HCC metastases, such as tumor vaccines, immunotherapy, etc., the survival rate has only slightly improved in recent decades. [0003] Metastasis is the main feature of tumor malignant behavior and an important cause of clinical treatment failure. Therefore, finding ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/44A61P35/00A61P35/04A61K31/34
CPCA61K31/34A61K31/44A61P35/00A61P35/04A61K2300/00Y02A50/30
Inventor 刘云刘芳朱欣婷晏容张建永李晓飞
Owner ZUNYI MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com